Dr. Schlesinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1703 Innovation Dr
Ste 2001
York, PA 17408Phone+1 717-801-0765Fax+1 410-427-5116
Summary
- I am a board certified medical oncologist and hematologist. Most of my practice is breast oncology but I am comfortable seeing all solid tumors and enjoy benign hematology. I am medical director of the St. Joseph Cancer Center, a member of the University of Maryland Medical System in Baltimore, Maryland.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Virginia Medical CenterResidency, Internal Medicine, 1997 - 2000
University of Pittsburgh School of MedicineClass of 1997
Certifications & Licensure
MD State Medical License 2019 - 2025
PA State Medical License 2004 - 2024
VA State Medical License 1997 - 2024
NC State Medical License 2003 - 2007- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Publications & Presentations
PubMed
- 8 citationsThe NPM-RAR fusion protein associated with the t(5;17) variant of APL does not interact with PML.Elizabeth A. Rush, Kimberly W. Schlesinger, Simon C. Watkins, Robert L. Redner
Leukemia Research. 2006-08-01 - 99 citationsPretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease.Margaret V. Ragni, Bijan Eghtesad, Kimberly W. Schlesinger, Igor Dvorchik, John J. Fung
Liver Transplantation. 2005-11-01
Press Mentions
Can Happy Hour Give You Cancer?October 25th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
